Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
Phone
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Jeffrey Rathmell, Ph.D.
- Co-Leader, Host-Tumor Interactions Research Program
- Cornelius Vanderbilt Professor of Immunobiology
- Professor of Pathology, Microbiology and Immunology
- Director, Vanderbilt Center for Immunobiology
615-322-3234
jeff.rathmell@vanderbilt.edu
Vanderbilt-Ingram Cancer Center
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
648-B Preston Research Building
2220 Pierce Ave
Nashville, TN 37232
Research Program
Departments/Affiliations
Profile
Education
- Ph.D., Immunology, Stanford University, Stanford, California (1997)
- B.S., Biology, University of Northern Iowa, Cedar Falls, Iowa (1991)
Research Emphasis
Immunometabolism in inflammatory disease, cancer, and anti-tumor immunity
Research Description
There has been a growing appreciation that metabolism is intimately linked to nearly all aspects of cell function and fate. The field of immunometabolism aims to understand how metabolic pathways are regulated in immune cells, how specific metabolic programs alter immune function, and how immunity in turn may influence metabolism. The Rathmell lab focuses on how metabolic pathways influence the function and fate of lymphocytes in inflammatory diseases, anti-tumor immunity, and in leukemia. Our work is highly interdisciplinary and involves the fields of immunology, cancer biology, and cell metabolism. Ultimately the goals of these projects are to exploit the specific metabolic programs of each cell type or activation state to selectively impact effector lymphocytes in inflammatory diseases and leukemic cells in cancer.
Publications
- Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, Taneja R, Kaplan MH, Rathmell JC, Dong H, Hitosugi T, Sun J. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality. Immunity. 2019 Sep 9/17/2019; 51(3): 491-507.e7. PMID: 31533057, PII: S1074-7613(19)30364-4, DOI: 10.1016/j.immuni.2019.08.013, ISSN: 1097-4180.
- Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J Immunother Cancer. 2019 Aug 8/14/2019; 7(1): 218. PMID: 31412954, PMCID: PMC6694548, PII: 10.1186/s40425-019-0704-z, DOI: 10.1186/s40425-019-0704-z, ISSN: 2051-1426.
- van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood [print-electronic]. 2019 Jul 7/4/2019; 134(1): 44-58. PMID: 31076448, PII: blood.2018885863, DOI: 10.1182/blood.2018885863, ISSN: 1528-0020.
- Savona MR, Rathmell JC. Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade. Cancer Discov. 2019 Jul; 9(7): 831-3. PMID: 31262744, PII: 9/7/831, DOI: 10.1158/2159-8290.CD-19-0510, ISSN: 2159-8290.
- Babaer D, Amara S, McAdory BS, Johnson O, Myles EL, Zent R, Rathmell JC, Tiriveedhi V. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. Cancers (Basel). 2019 May 5/14/2019; 11(5): PMID: 31091800, PMCID: PMC6562487, PII: cancers11050672, DOI: 10.3390/cancers11050672, ISSN: 2072-6694.
- Sinclair LV, Howden AJ, Brenes A, Spinelli L, Hukelmann JL, Macintyre AN, Liu X, Thomson S, Taylor PM, Rathmell JC, Locasale JW, Lamond AI, Cantrell DA. Antigen receptor control of methionine metabolism in T cells. Elife. 2019 Mar 3/27/2019; 8: PMID: 30916644, PMCID: PMC6497464, PII: 44210, DOI: 10.7554/eLife.44210, ISSN: 2050-084X.
- Freemerman AJ, Zhao L, Pingili AK, Teng B, Cozzo AJ, Fuller AM, Johnson AR, Milner JJ, Lim MF, Galanko JA, Beck MA, Bear JE, Rotty JD, Bezavada L, Smallwood HS, Puchowicz MA, Liu J, Locasale JW, Lee DP, Bennett BJ, Abel ED, Rathmell JC, Makowski L. Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1. J. Immunol [print-electronic]. 2019 Feb 2/15/2019; 202(4): 1265-86. PMID: 30659108, PMCID: PMC6360258, PII: jimmunol.1800002, DOI: 10.4049/jimmunol.1800002, ISSN: 1550-6606.
- Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin. Cancer Res [print-electronic]. 2019 Feb 2/1/2019; 25(3): 1036-49. PMID: 30327305, PMCID: PMC6361669, PII: 1078-0432.CCR-18-0706, DOI: 10.1158/1078-0432.CCR-18-0706, ISSN: 1078-0432.
- Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL, Hoehn KL, Rathmell JC, Bullock TNJ. Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. Sci Immunol. 2019 Jan 1/25/2019; 4(31): PMID: 30683669, PII: 4/31/eaap9520, DOI: 10.1126/sciimmunol.aap9520, ISSN: 2470-9468.
- Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM. Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. Cancer Immunol Res [print-electronic]. 2019 Jan; 7(1): 86-99. PMID: 30413431, PMCID: PMC6318034, PII: 2326-6066.CIR-17-0692, DOI: 10.1158/2326-6066.CIR-17-0692, ISSN: 2326-6074.
